Scholarlink

Background <p>Our objective was to evaluate the safety and immunogenicity of the COVID-19 mRNA vaccine (CS-2034) in Chinese adults, and to determine the optimal dosage with a favorable safety and immunogenicity profile.</p> Methods <p>This study was a phase II clinical trial conducted across multiple centers, employing a randomized, double-blinded, dose-exploration, placebo-controlled design which was registered at ClinicalTrials.gov under the identifier NCT05373472 (registration date: May 13, 2022).</p> Results <p>A total of 150 participants were randomized into low-dose vaccine, high-dose vaccine, and placebo groups. The vaccine CS-2034 was well tolerated, with adverse reactions largely mild to moderate and comparable across dose groups. Both dose levels induced strong neutralizing antibody responses against the ancestral SARS-CoV-2 strain, with high seroconversion and evidence of antibody persistence over time. In contrast, neutralizing activity against the Omicron BA.1 variant was limited and declined further after the peak response.</p> Conclusions <p>The 0.3 mL dose (low-dose vaccine) was selected for further development based on comparable immunogenicity and lower reactogenicity.</p> Clinical trial registration <p>The study was registered at ClinicalTrials.gov under the identifier NCT05373472 (registration date: May 13, 2022).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety, immunogenicity, persistence and dose evaluation of the CS-2034 mRNA COVID-19 vaccine: a phase II randomized controlled trial in healthy Chinese adults

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月20日

查看全文
  • Zhili Jin,
  • Jingxuan Wu,
  • Tao Huang,
  • Kexin Zhao,
  • Meijuan Zhang,
  • Jun Liu,
  • Jian Song,
  • Hang Yin,
  • Xiaofang Wu,
  • Jian Liu,
  • Tao Zhu,
  • Haitao Huang,
  • Jin Li,
  • Haomeng Wang,
  • Jinbo Gou,
  • Ruihua Dong

摘要

Background

Our objective was to evaluate the safety and immunogenicity of the COVID-19 mRNA vaccine (CS-2034) in Chinese adults, and to determine the optimal dosage with a favorable safety and immunogenicity profile.

Methods

This study was a phase II clinical trial conducted across multiple centers, employing a randomized, double-blinded, dose-exploration, placebo-controlled design which was registered at ClinicalTrials.gov under the identifier NCT05373472 (registration date: May 13, 2022).

Results

A total of 150 participants were randomized into low-dose vaccine, high-dose vaccine, and placebo groups. The vaccine CS-2034 was well tolerated, with adverse reactions largely mild to moderate and comparable across dose groups. Both dose levels induced strong neutralizing antibody responses against the ancestral SARS-CoV-2 strain, with high seroconversion and evidence of antibody persistence over time. In contrast, neutralizing activity against the Omicron BA.1 variant was limited and declined further after the peak response.

Conclusions

The 0.3 mL dose (low-dose vaccine) was selected for further development based on comparable immunogenicity and lower reactogenicity.

Clinical trial registration

The study was registered at ClinicalTrials.gov under the identifier NCT05373472 (registration date: May 13, 2022).